Trial intelligence / Profile preview

Temozolomide and pegylated liposomal doxorubicin in first-line treatment of glioblastoma (WHO grade IV)

2006-001375-38Phase 2Completed

Sponsor: Klinik und Poliklinik fÃ¼r Neurologie der UniversitÃ¤t Regensburg am Bezirksklinikum
Start: Jul 2006
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, single-arm trial of temozolomide and doxorubicin in glioblastoma (GBM), sponsored by Klinik und Poliklinik fÃ¼r Neurologie der UniversitÃ¤t Regensburg am Bezirksklinikum. Primary endpoint: Progression-free survival at 12 months (PFS-12). Started Jul 2006; status: completed.

Drugs

temozolomidedoxorubicin

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on 2006-001375-38.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-001375-38.